21 min listen
Four Is Better Than Three: Will We Finally Agree?
FromThe Hematologist
ratings:
Length:
23 minutes
Released:
Mar 18, 2024
Format:
Podcast episode
Description
In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Pieter Sonneveld, MD, PhD, a professor of hematology at the Erasmus University of Rotterdam in the Netherlands. They discuss Dr. Sonneveld’s recent paper, “Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma,” published in The New England Journal of Medicine. Dr. Chari wrote about Dr. Sonneveld’s paper in The Hematologist with his Diffusion article, “Four Is Better Than Three: Will We Finally Agree?” Disclosures: Dr. Chari has received consulting fees from Abbvie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, Forus, Genentech/Roche, Glaxo Smith Klein, Janssen, Karyopharm, Millenium/Takeda, and Sanofi/Genzyme and received research funding from Janssen. Dr. Sonneveld has served on the advisory board of Pfizer and has received research funding and served on the advisory board of Amgen, Bristol Myers Squibb, Celgene, Janssen, and Karyopharm.Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
Released:
Mar 18, 2024
Format:
Podcast episode
Titles in the series (100)
The Year's Best in Sickle Cell Disease with Dr. Alexis Thompson and Dr. Jason Gotlib: The first podcast of 2017 for The Hematologist: ASH News and Reports features Dr. Jason Gotlib (Stanford University School of Medicine) and Dr. Alexis Thompson (Ann and Robert H. Lurie Children's Hospital) having a conversation about the highlights of 201 by The Hematologist